Trials / Terminated
TerminatedNCT00008216
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (actual)
- Sponsor
- Columbia University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.
Detailed description
OBJECTIVES: * Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy. * Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity, relapse, graft-versus-host disease, and survival of patients treated with this regimen. OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0. Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months. PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
Conditions
- Adult Langerhans Cell Histiocytosis
- Childhood Langerhans Cell Histiocytosis
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Peripheral Blood Stem Cell Transplantation |
Timeline
- Start date
- 1996-07-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2003-01-27
- Last updated
- 2014-06-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00008216. Inclusion in this directory is not an endorsement.